We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Treating Alpelisib-Induced Hyperglycemia with Very Low Carbohydrate Diets and Sodium-Glucose Co-Transporter 2 Inhibitors: A Case Series.
- Authors
Blow, Tahj; Hyde, Parker N.; Falcone, John N.; Neinstein, Aaron; Vasan, Neil; Chitkara, Ritika; Hurd, Maurice A.; Sardesai, Sagar; Lustberg, Maryam B.; Flory, James H.; Volek, Jeff S.; Goncalves, Marcus D.
- Abstract
Alpelisib is a α-selective phosphatidylinositol 3-kinase (PI3K) inhibitor approved for treatment of postmenopausal women, and men, with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2–), PIK3CA-mutated, advanced breast cancer (ABC). Hyperglycemia is a common, on-target adverse effect that impairs treatment efficacy and increases the rate of treatment delays, dose reductions, and discontinuation. Currently, there are no clear guidelines on how to manage hyperglycemia due to alpelisib when metformin is not effective. In this case series, we review 3 subjects with ABC that developed hyperglycemia during alpelisib-fulvestrant therapy and were successfully managed with dietary and pharmacologic interventions. These cases provide anecdotal evidence to support the use of sodium-glucose co-transporter-2 inhibitors (SGLT2i) and very low carbohydrate diets to minimize hyperglycemia during alpelisib therapy.
- Subjects
SODIUM-glucose cotransporters; OBESITY; HYPERGLYCEMIA; LOW-carbohydrate diet; CASE studies; ENZYME inhibitors
- Publication
Integrative Cancer Therapies, 2021, Vol 20, p1
- ISSN
1534-7354
- Publication type
Article
- DOI
10.1177/15347354211032283